Chromatics Releases Fiscal Year Results.

NEW YORK--(BUSINESS WIRE)--April 1, 1997--Chromatics Color Sciences International, Inc. (NASDAQ: CCSI) announced its 1996 fiscal year results today.

Revenues for the fiscal year ended December 31, 1996 was $287,400 (a $500 decrease from 1995 revenues). Chromatics incurred net losses of $4,442,300 (net loss of $0.76 per share) and $2,494,300 (net loss of $.59 per share) for fiscal years 1996 and 1995, respectively. The $1,948,000 increase in such losses in 1996 as compared to 1995 is primarily attributable to $1,381,000 of expenses incurred to prepare and complete the company's FDA application and related patent application, $476,700 in patent application costs (including related research and development expenses), write-offs of uncollectable receivables and certain inventory, expenses for compensation of officers and employees, and legal fees and deferred costs incurred in connection with the company's financing activities and potential acquisition activities.

Chromatics Color Sciences International, Inc. is engaged in the business of color science, including the scientific color measurement and classification of human skin, certain color-sensitive consumer products, and in determining the color compatibility of such skin and product color classification for use in a variety of industries, including the cosmetic beauty aid and fashion industries, as well as technology development for potential medical applications involving the diagnosis and monitoring of certain chromogenic diseases. The company's common stock and warrants are traded on NASDAQ under the symbols "CCSI" and "CCSIW", respectively.

Except for the historical information contained herein, certain of the matters discussed are forward-looking statements that involve material risks to and uncertainties in the company's business which may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, the availability of any needed financing, the company's ability to implement its long range business plan for various applications for its technologies, the impact of competition, the obtaining of and compliance with regulatory approvals applicable to proposed application of the company's technology, the management of growth, and other risks and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission, including those set forth in the Form 10-KSB. -0-

    CHROMATICS COLOR SCIENCES INTERNATIONAL INC. AND SUBSIDIARY
              CONSOLIDATED STATEMENTS OF OPERATIONS

                                       Year Ended December 31,
                                         1996          1995

REVENUES

Lease, license and service contracts    $66,100      $167,000
Interest income                         220,800       117,800
Other                                       500         3,100
                                        287,400       287,900

COSTS AND EXPENSES:

Food and Drug Administration ("FDA")
 medical application expenses         1,281,500       207,000
Patent application costs (including
 $100,000 of FDA related costs and
 $282,300 of research and development
 costs in 1996)                         382,300       111,000
Research and development costs          194,400       419,500

General and administrative:

Compensation - officers and employees   810,500       556,100
Consultants                             205,900       238,500
Legal fees                              296,300       215,000
Accounting fees                          51,600        51,100
Rent and storage                        195,400       189,000
Insurance                               195,800       175,500
Travel and entertainment                 25,900        83,300
Repairs and maintenance                  85,100        57,000
Depreciation and amortization           178,600        52,900
Bad debt expense                        257,700        42,900
Payroll taxes                            80,000        61,700
Stock administrative fees                52,500        28,300
Interest                                 65,900        28,600
Other                                   370,300       264,800
                                    $ 4,729,700   $ 2,782,200

Net Loss                            $ 4,442,300   $ 2,494,300

Weighted average number of common
 shares and equivalents outstanding   5,825,006     4,231,600

Net loss per share                  $      0.76   $      0.59
-0-

CONTACT: Chromatics Color Sciences International

Darby Macfarlane, 212/717-6544

fax: [phone]